How much of the prior $100M authorization has LifeStance used?

The cash flow statement shows the Company repurchased $97.625 million of common stock during the first six months of 2026, indicating nearly full execution of the prior authorization approved in February 2026. This active repurchase activity reflects management's execution discipline.

Why did LifeStance renew the authorization at the same $100M level?

The filing does not explain the rationale for maintaining the same authorization level rather than increasing or decreasing it. The decision came after the Company reported strong Q2 results, 26% revenue growth, and raised full-year guidance, suggesting confidence in ongoing operational performance and capital generation.

Does this authorization replace or supplement the prior program?

The filing explicitly states the new authorization "replaces" the prior $100 million program approved February 24, 2026. This is a renewal, not an expansion—the prior program has been fully or substantially executed, and this new authorization begins a fresh $100 million authorization pool.

What is LifeStance's current leverage and cash position?

As of June 30, 2026, the Company had cash and cash equivalents of $225.9 million and net long-term debt of $259.0 million. Operating cash flow for the first six months was $133.0 million, providing substantial liquidity to support both the repurchase program and operational growth initiatives.

How many shares are outstanding and what is the share count impact?

As of June 30, 2026, LifeStance had 382.022 million shares issued and outstanding (down from 388.318 million at December 31, 2025), reflecting prior repurchase activity. The exact share count impact of the new $100M authorization will depend on future execution prices and execution timing.

LFST 8-K Filed 2026-08-05 New authorization

LifeStance authorizes new $100M share repurchase program

Mental health provider replaces prior $100M authorization amid strong Q2 results and raised FY guidance

Authorization$100M

MechanismOpen-market purchases, private

What the filing says

LifeStance Health Group, Inc. announced a new $100 million share repurchase authorization approved by its Board of Directors on August 6, 2026. The program replaces the Company's prior $100 million repurchase program that was approved on February 24, 2026. Repurchases may be made from time to time at the Company's discretion in the open market or through privately negotiated transactions, including accelerated share repurchase programs, subject to market conditions and other relevant factors.

The announcement came as part of LifeStance's second-quarter 2026 earnings release, in which the Company reported strong operational performance: revenue of $435.4 million (up 26% year-over-year), net income of $23.6 million compared to a net loss of $3.8 million in Q2 2025, and Adjusted EBITDA of $66.0 million (up 94% year-over-year). The Company also raised full-year 2026 guidance, increasing revenue expectations to $1.685–$1.725 billion and Adjusted EBITDA to $215–$235 million.

As of June 30, 2026, LifeStance had cash and cash equivalents of $225.9 million and net long-term debt of $259.0 million. The cash flow statement shows the Company repurchased $97.625 million of common stock during the first six months of 2026, indicating active execution under the prior authorization.

The Company's Board of Directors has approved a share repurchase program authorizing the repurchase of up to $100 million of the Company's outstanding common stock, which replaces the Company's prior $100 million repurchase program approved by the Board of Directors of the Company on February 24, 2026. Repurchases may be made from time to time at the Company's discretion in the open market or through privately negotiated transactions, including accelerated share repurchase programs, subject to market conditions and other relevant factors. — LifeStance Health Group, Inc. 8-K filing · View on SEC EDGAR →

What this means

LifeStance's $100 million repurchase authorization represents a renewal rather than an expansion of shareholder return capacity. The fact that the Company already deployed approximately $97.6 million under its prior February 2026 authorization—suggesting near-complete execution—indicates management confidence in capital allocation following strong operational momentum. With positive free cash flow generation of $87.9 million in Q2 2026 alone and improved profitability, the authorization demonstrates the Company's ability to balance growth investments with capital returns. The use of flexible execution mechanisms, including potential accelerated programs, provides optionality to time repurchases according to market conditions.

Frequently asked questions

How much of the prior $100M authorization has LifeStance used?: The cash flow statement shows the Company repurchased $97.625 million of common stock during the first six months of 2026, indicating nearly full execution of the prior authorization approved in February 2026. This active repurchase activity reflects management's execution discipline.
What execution methods are allowed under this program?: Repurchases may be made in the open market, through privately negotiated transactions, or via accelerated share repurchase (ASR) programs, subject to market conditions and other relevant factors. The flexibility allows management to choose timing and approach based on stock price and capital availability.
Why did LifeStance renew the authorization at the same $100M level?: The filing does not explain the rationale for maintaining the same authorization level rather than increasing or decreasing it. The decision came after the Company reported strong Q2 results, 26% revenue growth, and raised full-year guidance, suggesting confidence in ongoing operational performance and capital generation.
Does this authorization replace or supplement the prior program?: The filing explicitly states the new authorization "replaces" the prior $100 million program approved February 24, 2026. This is a renewal, not an expansion—the prior program has been fully or substantially executed, and this new authorization begins a fresh $100 million authorization pool.
What is LifeStance's current leverage and cash position?: As of June 30, 2026, the Company had cash and cash equivalents of $225.9 million and net long-term debt of $259.0 million. Operating cash flow for the first six months was $133.0 million, providing substantial liquidity to support both the repurchase program and operational growth initiatives.
How many shares are outstanding and what is the share count impact?: As of June 30, 2026, LifeStance had 382.022 million shares issued and outstanding (down from 388.318 million at December 31, 2025), reflecting prior repurchase activity. The exact share count impact of the new $100M authorization will depend on future execution prices and execution timing.

authorization healthcare mental-health-provider open-market asr cash-flow-positive

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.